Skip to main content

Table 4 Demographic and Clinical Characteristics of Belatacept and Control patients

From: Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept

Cohort characteristics Belatacept (N = 30) CNI (N = 56) P value
Age (y) 53.5 ± 26 52.0 ± 21 0.700
Donor age (y) 48.0 ± 23 46.0 ± 23 0.907
Gender (m/f) 20/10 19/37 0.956
Post-transplant diabetes 3/30 5/56 0.871
BMI 25.3 ± 4.1 22.9 ± 8.3 0.213
Systolic BP (mmHg) 134 ± 17 130 ± 51 0.076
Diastolic BP (mmHg) 84 ± 10 80 ± 13 0.054
Time after transplantation (m) 127.5 ± 91.3 113.0 ± 102.5 0.500
eGFR (mL/min) 22.5 ± 12 24.5 ± 14 0.583
eGFR < 25 mL/min 17/30 28/56 0.667
Proteinuria (mg/g creatinine) 840 ± 1166 280.5 ± 1270 0.157
Living donor transplants 8/30 8/56  
Pancreas/kidney 2/30 6/56  
Immunosuppression
 Tacrolimus 22/30 42/56 0.867
 Cyclosporine A 8/30 14/56 0.867
 Mycophenolic acid 27/30 54/56 0.227
 Azathioprin 2/30 0/56 0.052
 Steroid 24/30 45/56 0.969
DSA 14/30 19/56 0.336
h/o any rejection 15/30 20/56 0.201
aTCMR 3/30 7/56 0.732
aABMR 6/30 12/56 0.990
Histology before switch (m) 5 ± 11.3 9.5 ± 26.5 0.236
Biopsy scores
 glomerular scarring (%) 30.5 ± 33 28.5 ± 45 0.942
 cg 0.0 ± 3.0 0.0 ± 1.4 0.202
 ct 1.0 ± 1.0 1.0 ± 1.0 1.000
 ci 1.0 ± 1.0 1.0 ± 1.0 0.705
 cv 2.0 ± 2.0 1.0 ± 1.0 0.368
 mm 1.0 ± 2.0 1.0 ± 2.0 0.845
 ah 3.0 ± 0.0 2.75 ±1.0 0.003
 g 0.0 ± 1.0 0.0 ± 0.0 0.307
 t 0.0 ± 0.0 0.0 ± 0.0 0.865
 i 0.0 ± 0.0 0.0 ± 1.0 0.243
 v 0.0 ± 0.0 0.0 ± 0.0 0.129
 ptc 0.0 ± 0.0 0.0 ± 0.0 0.956
 diffuse ptc (y/n) 0/30 3/56 0.333
 C4d 0.0 ± 0.0 0.0 ± 0.0 1.000
 MVI sum score 0.0 ± 1.3 0.0 ± 1.0 0.448
 MVI sum score 2 7/30 8/56 0.295
  1. Data were expressed as medians (interquartile range), or numbers
  2. BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, DSA donor specific antibodies, h/o history of, aTCMR active T cell mediated rejection, aABMR active antibody-mediated rejection, MVI microvascular inflammation